Skip to main content
AVBP
NASDAQ Life Sciences

ArriVent Posts $40.3M Q3 Loss, $393M Cash Through Mid-2028 as FURVENT Review Continues

Tom Rudovsky · Reported by GlobeNewswire
More coverage: Biotech Stocks · Healthcare
Sentiment info
Neutral
Importance info
7
Price
$14.16
Mkt Cap
$698.197M
52W Low
$11.36
52W High
$35.83
52W Position info
25% above low
Off High info
60% below high
Rel. Volume info
0.7× avg
Market data snapshot near publication time

AVBP sits 25% above its 52-week low of $11.36.

Summary

ArriVent reported a $40.3M net loss for Q3 2026, with $393.2M in cash and investments that management says funds operations to mid-2028. The quarter's central issue remains firmonertinib: the Phase 3 FURVENT trial missed its primary PFS endpoint, and the company disclosed fuller data — median PFS of 11.0 months versus 9.5 months on chemotherapy (HR 0.75; p=0.0654) and a confirmed ORR of 60% versus 33%. Management is reviewing the dataset, including BICR versus investigator-assessed PFS differences in the chemo arm, and will give a firmonertinib update in Q1 2027. The ADC pipeline is the offset: ARR-217 showed a 44.8% ORR in colorectal cancer at 6 mg/kg, with Phase 1b data expected in the first half of 2027, and ARR-002 has dosed its first patient. Cash burn is steady — $122.2M used in operations over nine months versus $129.9M a year earlier — but the loss of R&D architect and co-founder Stuart Lutzker, alongside a new CMO, leaves execution on the remaining pipeline as the thing to prove.

At the time of this announcement, AVBP was trading at $14.16 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $698.2M. The 52-week trading range was $11.36 to $35.83. This news item was assessed with neutral market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.


Price Chart

Share this article

Copied!

AVBP - Latest Insights

AVBP
Nov 09, 2026, 4:21 PM EST
Filing Type: 10-Q
Importance Score:
7
Price at Filing: $14.16
Real-time Price: $14.16 info
Change: $0 (0%) info
Market Cap: $698.197M info
AVBP
Nov 09, 2026, 4:05 PM EST
Filing Type: 8-K
Importance Score:
7
Price at Filing: $14.16
Real-time Price: $14.16 info
Change: $0 (0%) info
Market Cap: $698.197M info
AVBP
Oct 26, 2026, 6:00 AM EDT
Filing Type: 8-K
Importance Score:
7
Price at Filing: $23.30
Real-time Price: $14.16 info
Change: -$9.14 (-39%) info
Market Cap: $698.197M info
AVBP
Oct 12, 2026, 5:29 PM EDT
Source: Reuters
Importance Score:
7
Price at Filing: $16.46
Real-time Price: $14.16 info
Change: -$2.30 (-14%) info
Market Cap: $698.197M info
AVBP
Oct 06, 2026, 8:07 AM EDT
Filing Type: 8-K
Importance Score:
9
Price at Filing: $28.70
Real-time Price: $14.16 info
Change: -$14.54 (-51%) info
Market Cap: $698.197M info